Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 1

Drug Profile

GEN 1

Alternative Names: EGEN-001; GEN-1; IL-12 gene therapy - Celsion Corporation; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Celsion Corporation; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; phIL-12-005/PPC

Latest Information Update: 20 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Expression Genetics
  • Developer Celsion Corporation; Gynecologic Oncology Group
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Gene transference; Immunomodulators; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Glioblastoma
  • No development reported Colorectal cancer

Most Recent Events

  • 04 Mar 2019 Celsion completes a phase I OVATION I trial in Fallopian tube cancer and Peritoneal Cancer (Newly diagnosed, First-line therapy, Combination therapy, Late-stage disease) in USA (Intraperitoneal) (NCT02480374)
  • 04 Mar 2019 Additional efficacy, pharmacodynamic and adverse events data from a phase I OVATION I trial in Ovarian cancer released by Celsion Corporation (Intraperitoneal)
  • 24 Oct 2018 Updated efficacy data from the phase Ib OVATION I trial in Ovarian cancer released by Celsion Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top